For US Healthcare Professionals Only
Once-weekly REZZAYO™

Invasive candidiasis management, simplified with once-weekly REZZAYO™

Indication

REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.1

Patients with invasive candidiasis or candidemia tend to be critically ill and may be on other therapies, such as broad-spectrum antibiotics, corticosteroids, immunosuppressants, or anticancer medications. The choice of antifungal can further complicate these factors.1-4

When you start REZZAYO™1

No clinically relevant drug-
drug interactions

No dose adjustments for
special populations

No requirement for a PICC or
central line

No impact on QTc interval

Can be used in patients with
renal impairment

Administer in a variety of
care settings

PICC=peripherally inserted central catheter; QTc=corrected QT interval.

The first echinocandin in more than 15 years1,5,8,9

The once-weekly dosing schedule of REZZAYO™ may help simplify treatment logistics1,2

 

Allows patients to avoid an invasive PICC but still benefit from echinocandin treatment

 

May help facilitate continuity of echinocandin treatment and reduce unnecessary switching or discontinuation of life-saving medication as the patient moves to lower-intensity care or outpatient treatment

 

Could save time and staff resources associated with daily infusions related to management of invasive candidiasis

 

Has the potential to reduce the number of healthcare touchpoints for patients needing echinocandin treatment

 

Offers patients who cannot take oral medications a once-weekly option6

 

Adherence is of the utmost importance for life-saving medications. The once-weekly HCP-administered dose of REZZAYO™ may provide greater transparency into patient adherence7

High early plasma concentrations

See PK Data

INDICATION AND USAGE

REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data.

Limitations of Use

REZZAYO™ has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.

IMPORTANT SAFETY INFORMATION

Contraindications

REZZAYO™ is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

Warnings and Precautions

  • Infusion-related Reactions: REZZAYO™ may cause infusion-related reactions, including flushing, sensation of warmth, urticaria, nausea, or chest tightness. If these reactions occur, slow or pause the infusion.
  • Photosensitivity: REZZAYO™ may cause photosensitivity. Advise patients to use protection from sun exposure and other sources of UV radiation.
  • Hepatic Adverse Reactions: Abnormalities in liver tests have been seen in clinical trial patients treated with REZZAYO™. Monitor patients who develop abnormal liver tests and evaluate patients for their risk/benefit of continuing REZZAYO™ therapy.

Adverse Reactions

Most common adverse reactions (incidence ≥ 5%) are hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, abdominal pain, constipation, and hypophosphatemia.

Please see full Prescribing Information for REZZAYO™ (rezafungin for injection).

See more

INDICATION AND USAGE

REZZAYO™ (rezafungin for injection) is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the

IMPORTANT SAFETY INFORMATION

Contraindications

REZZAYO™ is contraindicated in patients with known hypersensitivity to rezafungin or other echinocandins.

References:1. REZZAYO™. Prescribing information. Melinta Therapeutics, LLC; 2023. 2. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026. doi:10.1038/nrdp.2018.26 3. Calandra T, Roberts JA, Antonelli M, Bassetti M, Vincent JL. Diagnosis and management of invasive candidiasis in the ICU: an updated approach to an old enemy. Crit Care. 2016;20(1):125. doi:10.1186/s13054-016-1313-6 4. Demir KK, Butler-Laporte G, Del Corpo O, et al. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: a systematic review and network meta-analysis. Mycoses. 2021;64(9):1098-1110. doi:10.1111/myc.13290 5. U.S. Food and Drug Administration. Drug approval package: Eraxis (anidulafungin injection). April 14, 2006. Accessed April 27, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021632_021948_EraxisTOC.cfm#:~:text=Approval%20Date%3A%2002%2F17%2F2006 6. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-e50. doi:10.1093/cid/civ933 7. World Health Organization. Adherence to long-term therapies: evidence for action. Accessed May 15, 2023. https://apps.who.int/iris/handle/10665/42682 8. U.S. Food and Drug Administration. Drug approval package: Mycamine (Micafungin Sodium). March 16, 2005. Accessed October 5, 2023. 9.U.S. Food and Drug Administration. Drug approval package: Cancidas (Caspofungin Acetate). January 26, 2001. Accessed October 5, 2023.